on October 23, 2003
Published online before print October 23, 2003, doi: 10.1161/01.STR.0000092488.40085.15
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 23, 2003
From the Centre for Vascular Research, University of Nottingham, Nottingham, UK. * To whom correspondence should be addressed. E-mail: philip.bath{at}nottingham.ac.uk.
Background--High blood pressure is a risk factor for stroke recurrence. We assessed the effectiveness of lowering blood pressure in preventing recurrent vascular events in patients with previous stroke or transient ischemic attack. Summary of Review--We performed a systematic review and meta-regression of completed randomized controlled trials that investigated the effect of lowering blood pressure on recurrent vascular events in patients with prior ischemic or hemorrhagic stroke or transient ischemic attack. Trials were identified from searches of 3 electronic databases (Cochrane Library, EMBASE, MEDLINE). Seven randomized controlled trials, with 8 comparison groups, were included. Lowering blood pressure or treating hypertension with a variety of antihypertensive agents reduced stroke (odds ratio [OR], 0.76; 95% CI, 0.63 to 0.92), nonfatal stroke (OR, 0.79; 95% CI, 0.65 to 0.95), myocardial infarction (OR, 0.79; 95% CI, 0.63 to 0.98), and total vascular events (OR, 0.79; 95% CI, 0.66 to 0.95). No effect was seen on vascular or all-cause mortality. Heterogeneity was present for several outcomes and was partly related to the class of antihypertensive drugs used; angiotensin-converting enzyme inhibitors and diuretics separately, and especially together, reduced vascular events, while Conclusions--Evidence from randomized controlled trials supports the use of antihypertensive agents in lowering blood pressure for the prevention of vascular events in patients with previous stroke or transient ischemic attack. Vascular prevention is associated positively with the magnitude by which blood pressure is reduced.
Accepted on June 24, 2003
Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events. A Systematic Review
Parveen Rashid MRCP(UK);
-receptor antagonists had no discernable effect. The reduction in stroke was related to the difference in systolic blood pressure between treatment and control groups (P=0.002).
Key words: adrenergic beta-antagonists • angiotensin-converting enzyme inhibitors • blood pressure • cardiovascular diseases, prevention and control • diuretics • myocardial infarction • stroke
This article has been cited by other articles:
 |
|
 |
|
  D S Lasserson Initial management of suspected transient cerebral ischaemia and stroke in primary care: implications of recent research Postgrad. Med. J., August 1, 2009; 85(1006): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Diener and C. Weimar Update of secondary stroke prevention Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1718 - 1724. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Rafnsson, I. J Deary, and F. Fowkes Peripheral arterial disease and cognitive function Vascular Medicine, February 1, 2009; 14(1): 51 - 61. [Abstract] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr Secondary Prevention of Atherothrombotic Events After Ischemic Stroke Mayo Clin. Proc., January 1, 2009; 84(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Talelli and R. J. Greenwood Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 387 - 405. [Abstract] [PDF]
|
|
|
|
 |
|
 A. I. Qureshi Acute Hypertensive Response in Patients With Stroke: Pathophysiology and Management Circulation, July 8, 2008; 118(2): 176 - 187. [Full Text] [PDF]
|
|
|
|
 |
|
 C Sudlow Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management Practical Neurology, June 1, 2008; 8(3): 141 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Touze, J. Coste, M. Voicu, J. Kansao, R. Masmoudi, B. Doumenc, P. Durieux, and J.-L. Mas Importance of In-Hospital Initiation of Therapies and Therapeutic Inertia in Secondary Stroke Prevention: IMplementation of Prevention After a Cerebrovascular evenT (IMPACT) Study Stroke, June 1, 2008; 39(6): 1834 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nassief and J. D. Marsh Statin Therapy for Stroke Prevention Stroke, March 1, 2008; 39(3): 1042 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Turan, G. Cotsonis, M. J. Lynn, S. Chaturvedi, M. Chimowitz, and for the Warfarin-Aspirin Symptomatic Intracranial Relationship Between Blood Pressure and Stroke Recurrence in Patients With Intracranial Arterial Stenosis Circulation, June 12, 2007; 115(23): 2969 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hackam and J. D. Spence Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study Stroke, June 1, 2007; 38(6): 1881 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Laowattana and S. M. Oppenheimer Protective effects of beta-blockers in cerebrovascular disease Neurology, February 13, 2007; 68(7): 509 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Brown, K. Brunnhuber, K. Chalkidou, I. Chalmers, M. Clarke, M. Fenton, C. Forbes, J. Glanville, N. J Hicks, J. Moody, et al. How to formulate research recommendations. BMJ, October 14, 2006; 333(7572): 804 - 806. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Paul and A. G. Thrift Control of Hypertension 5 Years After Stroke in the North East Melbourne Stroke Incidence Study Hypertension, August 1, 2006; 48(2): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M.W. Bath and N. Sprigg Control of Blood Pressure After Stroke Hypertension, August 1, 2006; 48(2): 203 - 204. [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, L. Thijs, and J. A. Staessen Blood Pressure Lowering for Primary and Secondary Prevention of Stroke Hypertension, August 1, 2006; 48(2): 187 - 195. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Muntner, K. B. DeSalvo, R. P. Wildman, P. Raggi, J. He, and P. K. Whelton Trends in the Prevalence, Awareness, Treatment, and Control of Cardiovascular Disease Risk Factors among Noninstitutionalized Patients with a History of Myocardial Infarction and Stroke Am. J. Epidemiol., May 15, 2006; 163(10): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation, March 14, 2006; 113(10): e409 - e449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, February 1, 2006; 37(2): 577 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ovbiagele, C. S. Kidwell, S. Starkman, S. L. Selco, V. Rajajee, T. Razinia, and J. L. Saver Angiotensin 2 type 2 receptor activity and ischemic stroke severity Neurology, September 27, 2005; 65(6): 851 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Paraskevas, S. S. Daskalopoulou, M. E. Daskalopoulos, and C. D. Liapis Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence? Angiology, September 1, 2005; 56(5): 539 - 552. [Abstract] [PDF]
|
|
|
|
 |
|
 Drugs to prevent vascular events after stroke DTB, July 1, 2005; 43(7): 53 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Loewen and G. W. Forsyth Structure and Function of CLCA Proteins Physiol Rev, July 1, 2005; 85(3): 1061 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M.W. Bath, L. Zhao, and S. Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C12 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Amar, J. P. Cambou, E. Touze, V. Bongard, G. Jullien, A. Vahanian, G. Coppe, J. L. Mas, and on behalf of ECLAT1 Study Investigators Comparison of Hypertension Management After Stroke and Myocardial Infarction: Results From ECLAT1--A French Nationwide Study Stroke, July 1, 2004; 35(7): 1579 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W Muir Secondary prevention for stroke and transient ischaemic attacks: Author's reply BMJ, April 10, 2004; 328(7444): 897 - 897. [Full Text]
|
|
|
|
 |
|
 Other articles noted: 14 Nov 2003 to 30 Jan 2004 Evid. Based Nurs., April 1, 2004; 7(2): e2 - e2. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted Evid. Based Med., March 1, 2004; 9(2): 63 - 64. [Full Text] [PDF]
|
|